Get Cash Back and $0 Commissions + The Power of TradeStation
Natus Medical Announces First Quarter 2019 Financial Results
Globe Newswire 25-Apr-2019 4:06 PM
First quarter revenue of $114.8 million
First quarter GAAP loss per share of $0.74; non-GAAP earnings per share of $0.09
PLEASANTON, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:BABY) (the "Company" or "Natus"), a leading provider of medical devices and services, today announced financial results for the three months ended March 31, 2019.
Key Results During the Quarter
Achieved high end of revenue expectations with earlier than expected completion of product registrations
GAAP and Non-GAAP gross margin increased due to better product mix and lower production costs
Announced our "One Natus" reorganization, streamlining our operations with expected benefits of over $4.0 million in 2019
Announced the exit of $26.4 million (fiscal year 2018) of non-profitable and non-core businesses (Neurocom, GND and Medix)
Generated $16.3 million in cash flow, excluding cash used for restructuring
Reduced long-term debt by $5.0 million
For the first quarter ended March 31, 2019, the Company reported revenue of $114.8 million, a decrease of 10.7% compared to $128.6 million reported for the first quarter 2018. GAAP gross profit margin was 58.1% during the first quarter of 2019 compared to 55.7% in the first quarter 2018. GAAP net loss was $24.8 million, or $0.74 per share, compared with GAAP net loss of $3.1 million, or $0.10 per share in the first quarter 2018. The GAAP net loss includes a $14.8 million non-cash charge for foreign currency cumulative translation adjustment related to the divestiture of the Medix business in Argentina.
Non-GAAP earnings per diluted share was $0.09 for the first quarter 2019, compared to $0.24 in the first quarter 2018. Non-GAAP net income was $3.1 million for the first quarter 2019 compared to the prior year's first quarter non-GAAP net income of $8.0 million. Non-GAAP gross profit margin was 59.7% in the first quarter 2019 compared to 59.0% reported for the first quarter of 2018.
"Our first quarter results reflect performance at the high end of our expectations. Within our Neuro end market, EEG grew 12.5% year-over-year. Otoscan continued to ramp up in Audiology and our phototherapy products within Newborn care grew significantly with the relaunch of our neoBlue line of products," said Jonathan Kennedy, President and Chief Executive Officer of Natus. "We have made progress on many fronts with our "One Natus" initiative since its announcement in January. The new organization structure is in place and we have begun to realize financial benefits as well as improved operational efficiency of "One Natus" during the quarter."
"Our previously announced divestiture of Medix marks another step toward making Natus more streamlined and profitable. This divestiture, along with those announced in January will reduce revenue, but increase our ongoing margins and earnings and allow us to focus on our best opportunities," Kennedy continued. "Year-over-year revenue growth in the first quarter was 2.7% after adjusting for the exited businesses and discontinued products."
Financial Guidance
For the second quarter of 2019, the Company's revenue guidance is expected to be between $121.0 million and $125.0 million and non-GAAP earnings per share guidance is expected to be between $0.25 and $0.32.
For the full year 2019, the Company's revenue expected guidance was updated to be between $489.0 million and $505.0 million from $490.0 million and $510.0 million and non-GAAP earnings expected per share guidance was updated to be between $1.17 and $1.44 from $1.12 and $1.49.
The Company's non-GAAP earnings per share guidance excludes charges for amortization expense associated with intangible assets from prior acquisitions, certain other expenses, and related tax effects, which the Company expects to be approximately $5.2 million and $37.7 million for the second quarter 2019 and full year, respectively, and which the Company expects will reduce GAAP earnings per share by approximately $0.15 and $1.12 for the respective periods.
Use of Non-GAAP Financial Measures
The Company presents in this release its non-GAAP net income, non-GAAP earnings per share, non-GAAP gross margin and non-GAAP operating margin results which exclude amortization expense associated with certain acquisition-related intangibles, restructuring charges, certain discrete items, direct costs of acquisitions, and the related tax effects. A reconciliation between non-GAAP and GAAP financial measures is included in this press release.
The Company believes that the presentation of results excluding these charges or gains provides meaningful supplemental information to both management and investors that is indicative of the Company's core operating results and better reflects the ongoing economics of the Company's operations. The Company believes these non-GAAP financial measures facilitate comparison of operating results across reporting periods.
Specifically, the Company excludes the following charges, gains, and their related tax effects in the calculation of non-GAAP net income, non-GAAP earnings per share and non-GAAP operating expense: 1) Non-cash amortization expense associated with certain acquisition-related intangibles. The charges reflect an estimate of the cost of acquired intangible assets over their estimated useful lives. 2) Restructuring and other non-recurring charges. The Company has over time completed multiple acquisitions of other companies and businesses. Following an acquisition the Company will, as it determines appropriate, initiate restructuring events to eliminate redundant costs. Restructuring expenses, which are excluded in the non-GAAP items, are exclusively related to permanent reductions in our workforce and redundant facility closures. Other non-recurring costs are associated with the transition of the executive management team. These costs can include stock compensation from accelerated vesting of stock, severance payouts and related payroll expenses. 3) Certain discrete items. These items represent significant infrequent charges or gains that management believes should be viewed outside of normal operating results, and each significant discrete transaction is evaluated to determine whether it should be excluded from non-GAAP reporting. These items are specifically identified when they occur. 4) Direct costs of acquisitions. These are direct acquisition-related costs that occur when the Company makes an acquisition, such as professional fees, due diligence costs, and earn-out adjustments.
The Company applies GAAP methodologies in computing its non-GAAP tax provision by determining the annual expected effective tax rate after taking into account items excluded for non-GAAP financial reporting purposes. The Company's non-GAAP tax expense and its non-GAAP effective tax rate are generally higher than its GAAP tax expense and GAAP effective tax rate because the income subject to taxes would be higher due to the effect of the expenses excluded from non-GAAP financial reporting. The nature of each quarterly discrete transaction will be evaluated to determine whether it should be excluded from non-GAAP reporting.
The Company's management uses these non-GAAP financial measures in assessing the Company's performance and when planning, forecasting, and analyzing future periods and the Company believes that investors also benefit from being able to refer to these non-GAAP financial measures along with the GAAP operating results. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated.
Conference Call
Natus has scheduled an investment-community conference call to discuss this announcement beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) today, April 25, 2019. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domestic callers, or 1-508-637-5658 for international callers, and entering reservation code 8493239. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-855-859-2056 for domestic callers, or 1-404-537-3406 for international callers, and entering reservation code 8493239. The conference call also will be available real-time via the Internet at http://investor.natus.com, and a recording of the call will be available on the Company's Web site for 90 days following the completion of the call.
About Natus Medical Incorporated
Natus is a leading provider of neurology, newborn care, and hearing and balance assessment healthcare products and services used for the screening, treatment and monitoring of common medical conditions in newborn care, hearing, balance impairment, neurological dysfunction, and sleep disorders.
Additional information about Natus Medical can be found at www.natus.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will", "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. These forward-looking statements include, without limitation, statements regarding creating a more efficient operating model, creating a stronger and more profitable company, enhancing focus on operational excellence, positioning the company for growth and driving long-term value for stakeholders. These statements relate to current estimates and assumptions of our management as of the date of this press release and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. The Company's future results could differ materially due to a number of factors, including the ability of the Company to realize the anticipated benefits from its new structure or from its consolidation strategy, effects of competition, the Company's ability to successfully integrate and achieve its profitability goals from recent acquisitions, the demand for Natus products and services, the impact of adverse global economic conditions and changing governmental regulations, including foreign exchange rate changes, on the Company's target markets, the Company's ability to expand its sales in international markets, the Company's ability to maintain current sales levels in a mature domestic market, the Company's ability to control costs, risks associated with bringing new products to market, and the Company's ability to fulfill product orders on a timely basis, as well as those factors identified under the heading Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Natus disclaims any obligation to update information contained in any forward looking statement, except as required by law.
Natus Medical Incorporated Drew Davies Executive Vice President and Chief Financial Officer (925) 223-6700 InvestorRelations@Natus.com
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited)
(in thousands, except per share amounts)
Quarter Ended
March 31, 2019
March 31, 2018
Revenue
$
114,757
$
128,609
Cost of revenue
46,370
55,369
Intangibles amortization
1,756
1,587
Gross profit
66,631
71,653
Gross profit margin
58.1
%
55.7
%
Operating expenses:
Marketing and selling
33,729
35,872
Research and development
13,058
15,443
General and administrative
16,306
17,448
Intangibles amortization
3,786
4,806
Restructuring
23,939
812
Total operating expenses
90,818
74,381
Income (loss) from operations
(24,187
)
(2,728
)
Interest expense
(1,506
)
(1,949
)
Other income (expense)
(605
)
128
Income (loss) before tax
(26,298
)
(4,549
)
Provision for income tax expense (benefit)
(1,524
)
(1,401
)
Net loss
$
(24,774
)
$
(3,148
)
Loss per share:
Basic
$
(0.74
)
$
(0.10
)
Diluted
$
(0.74
)
$
(0.10
)
Weighted-average shares:
Basic
33,590
32,760
Diluted
33,590
32,760
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands)
March 31,
December 31,
2019
2018
ASSETS
Current assets:
Cash and investments
$
54,035
$
56,373
Accounts receivable
111,956
127,041
Inventories
84,927
79,736
Other current assets
24,006
22,625
Total current assets
274,924
285,775
Property and equipment
26,280
22,913
Operating lease right-of-use assets
18,982
—
Goodwill and intangible assets
279,595
287,097
Deferred income tax
22,522
22,639
Other assets
21,331
19,716
Total assets
$
643,634
$
638,140
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
25,925
$
28,805
Short-term debt
35,000
35,000
Accrued liabilities
72,800
52,568
Deferred revenue
19,173
17,073
Total current liabilities
152,898
133,446
Long-term liabilities:
Long-term debt
64,522
69,474
Deferred income tax
16,699
16,931
Operating lease liabilities
15,234
—
Other long-term liabilities
21,351
19,845
Total liabilities
270,704
239,696
Total stockholders' equity
372,930
398,444
Total liabilities and stockholders' equity
$
643,634
$
638,140
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
(in thousands)
Quarter Ended
March 31, 2019
March 31, 2018
Operating activities:
Net loss
$
(24,775
)
$
(3,148
)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Provision for losses on accounts receivable
600
918
Depreciation and amortization
7,711
7,915
(Gain) loss on disposal of property and equipment
179
52
Warranty reserve
354
(1,125
)
Share-based compensation
2,554
2,362
Impairment of intangible assets held for sale
354
—
Reclassification of currency translation adjustment for held for sale entities
14,785
—
Changes in operating assets and liabilities:
Accounts receivable
14,499
(2,242
)
Inventories
(7,421
)
2,885
Prepaid expenses and other assets
(677
)
(5,390
)
Accounts payable
(2,613
)
(622
)
Accrued liabilities
(685
)
3,319
Deferred revenue
2,137
1,314
Deferred income tax
103
87
Net cash provided by (used in) operating activities
7,105
6,325
Investing activities:
Purchases of property and equipment
(2,461
)
(2,473
)
Net cash used in investing activities
(2,461
)
(2,473
)
Financing activities:
Proceeds from stock option exercises and ESPP
268
577
Repurchase of common stock
—
(4,736
)
Taxes paid related to settlement of equity awards
(1,567
)
(19
)
Principal payments of financing lease liability
(165
)
—
Contingent consideration earn-out
—
(147
)
Payments on borrowings
(5,000
)
(25,000
)
Net cash used in financing activities
(6,464
)
(29,325
)
Exchange rate changes effect on cash and cash equivalents
(518
)
994
Net decrease in cash and cash equivalents
(2,338
)
(24,479
)
Cash and cash equivalents, beginning of period
56,373
88,950
Cash and cash equivalents, end of period
$
54,035
$
64,471
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited)
(in thousands, except per share amounts)
Quarter Ended
March 31, 2019
March 31, 2018
GAAP based results:
Loss before provision for income tax
$
(26,298
)
$
(4,549
)
Non-GAAP adjustments:
Intangibles amortization (COGS)
1,756
1,587
Recall accrual and remediation efforts (COGS)
(255
)
268
Restructuring and other non-recurring costs (COGS)
251
—
Direct costs of acquisitions (COGS)
83
2,408
Intangibles amortization (OPEX)
3,786
4,806
Direct costs of acquisitions (M&S)
17
22
Recall accrual and remediation efforts (R&D)
—
1,846
Direct costs of acquisitions (R&D)
46
46
Restructuring and other non-recurring costs (OPEX)
24,231
967
Direct costs of acquisitions (G&A)
45
2,391
Restructuring and other non-recurring costs (OI&E)
—
368
Litigation (OPEX)
687
242
Non-GAAP income before provision for income tax
4,349
10,402
Income tax expense, as adjusted
$
1,241
$
2,375
Non-GAAP net income
$
3,108
$
8,027
Non-GAAP earnings per share:
Basic
$
0.09
$
0.25
Diluted
$
0.09
$
0.24
Weighted-average shares used to compute
Basic non-GAAP earnings per share
33,590
32,760
Diluted non-GAAP earnings per share
33,709
33,149
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited)
(in thousands, except per share amounts)
Quarter Ended
March 31, 2019
March 31, 2018
GAAP Gross Profit
$
66,631
$
71,653
Amortization of intangibles
1,756
1,587
Direct cost of acquisitions
83
2,408
Recall accrual and remediation efforts
(255
)
268
Restructuring and other non-recurring costs
251
—
Non-GAAP Gross Profit
$
68,466
$
75,916
Non-GAAP Gross Margin
59.7
%
59.0
%
GAAP Operating Loss
$
(24,187
)
$
(2,728
)
Amortization of intangibles
5,542
6,393
Recall accrual and remediation efforts
(255
)
2,114
Litigation
687
242
Restructuring and other non-recurring costs
24,482
967
Direct cost of acquisitions
191
4,867
Non-GAAP Operating Profit
$
6,460
$
11,855
Non-GAAP Operating Margin
5.6
%
9.2
%
GAAP Income tax benefit
$
(1,524
)
$
(1,401
)
Effect of accumulated change of pretax income
3,044
3,721
Effect of change in annual expected tax rate
(102
)
(53
)
Repatriation tax adjustment
(177
)
188
Stock-based compensation adjustment
—
(80
)
Non-GAAP Income tax expense
$
1,241
$
2,375
Quarter Ended
Year Ended
June 30, 2019
December 31, 2019
GAAP EPS Guidance
$0.10 -$0.17
$0.05 - $0.32
Amortization of Intangibles
0.18
0.68
Restructuring and other non-recurring costs
0.01
0.77
Direct cost of acquisitions
0.01
0.01
Tax effect
(0.05)
(0.35)
Non-GAAP EPS Guidance
$0.25 - $0.32
$1.17 - $1.44
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
GROSS MARGIN BY END MARKETS (unaudited)
(in thousands)
Year Ended
March 31, 2019
March 31, 2018
Neuro:
Revenue
$
62,390
$
65,947
Cost of revenue
23,089
27,894
Intangibles amortization
942
650
Gross profit
$
38,359
$
37,403
Gross profit margin
61.5
%
56.7
%
Newborn care:
Revenue
$
26,879
$
30,891
Cost of revenue
11,038
11,708
Intangibles amortization
66
120
Gross profit
$
15,775
$
19,063
Gross profit margin
58.7
%
61.7
%
Audiology:
Revenue
$
25,488
$
31,771
Cost of revenue
12,243
15,767
Intangibles amortization
748
817
Gross profit
$
12,497
$
15,187
Gross profit margin
49.0
%
47.8
%
Consolidated:
Revenue
$
114,757
$
128,609
Cost of revenue
46,370
55,369
Intangibles amortization
1,756
1,587
Gross profit
$
66,631
$
71,653
Gross profit margin
58.1
%
55.7
%
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP GROSS MARGIN BY END MARKETS (unaudited)
(in thousands)
Year Ended
March 31, 2019
March 31, 2018
Neuro:
GAAP Gross Profit
$
38,359
$
37,403
Amortization of intangibles
942
650
Acquisition charges
83
2,408
Non-GAAP Gross Profit
$
39,384
$
40,461
Non-GAAP Gross Margin
63.1
%
61.4
%
Newborn care:
GAAP Gross Profit
$
15,775
$
19,063
Amortization of intangibles
66
120
Recall accrual and remediation efforts
(255
)
268
Restructuring and other non-recurring costs
76
—
Non-GAAP Gross Profit
$
15,662
$
19,451
Non-GAAP Gross Margin
58.3
%
63.0
%
Audiology:
GAAP Gross Profit
$
12,497
$
15,187
Amortization of intangibles
748
817
Restructuring and other non-recurring costs
175
—
Non-GAAP Gross Profit
$
13,420
$
16,004
Non-GAAP Gross Margin
52.7
%
50.4
%
Consolidated:
GAAP Gross Profit
$
66,631
$
71,653
Amortization of intangibles
1,756
1,587
Acquisition charges
83
2,408
Recall accrual and remediation efforts
(255
)
268
Restructuring and other non-recurring costs
251
—
Non-GAAP Gross Profit
$
68,466
$
75,916
Non-GAAP Gross Margin
59.7
%
59.0
%
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
GEOGRAPHIC REVENUE (unaudited)
(in thousands)
Quarter Ended
March 31, 2019
March 31, 2018
Consolidated Revenue:
United States
$
66,067
$
68,688
International
48,690
59,921
Totals
$
114,757
$
128,609
United States
58
%
53
%
International
42
%
47
%
Totals
100
%
100
%
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
REVENUE AFTER EXITED PRODUCTS (unaudited)
(in thousands)
Quarter Ended
Year Ended
March 31, 2019
March 31, 2018
December 31, 2018
December 31, 2017
Revenue
$
114.8
$
128.6
$
530.9
$
501.0
Newborn care
(2.3
)
(6.1
)
(20.6
)
(35.0
)
Neuro
(0.9
)
(3.3
)
(14.3
)
(14.6
)
Audiology
—
(6.5
)
(7.9
)
(6.9
)
Impact of ship holds
3.8
—
—
—
Revenue after exited products/ship holds
$
115.5
$
112.6
$
488.1
$
444.5
Note: Newborn care, Neuro, and Audiology include exited businesses (GND, Neurocom, Medix) and other end of sales products.
